AI in personalized cancer medicine: New therapies require flexible and safe approval conditions

New, AI-based therapies require a flexible and safe legal framework in order to reach patients quickly and safely. In a new paper, published in npj Precision Oncology, researchers from Dresden, Leipzig, Marburg and Paris provide an overview of possible AI-based applications for personalized cancer medicine and the associated regulatory challenges. They emphasize that the current rigid and slow approval requirements impede technological progress and argue for an adaptation of the existing regulations.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup